Core Insights - Codexis (NASDAQ: CDXS) is transitioning from selling enzyme parts to becoming an integrated supplier of siRNA through their ECO synthesis technology, which aims to enhance the efficiency of pharmaceutical research and production [1] Group 1: Company Overview - Codexis specializes in enzymatic solutions that improve pharmaceutical research and production efficiency [1] Group 2: Technological Development - The company is evolving its business model to include integrated siRNA supply alongside its existing enzyme offerings, leveraging its ECO synthesis technology [1]

Wall Street expects a year-over-year decline in earnings on lower revenues when Codexis (CDXS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move low ...